Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19. #COVID19 #SARScov2 #coronavirus

Feature | Coronavirus (COVID-19) | Marianne Pop, Pharm.D, BCPS

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

It has been more than three months since the word coronavirus was uttered on everyone’s lips and all over the social ...

March 24, 2020

The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.

Feature | Pharmaceuticals

FDA Clears Bempedoic Acid Non-statin LDL-cholesterol Lowering Drug

February 24, 2020 — The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an ...

February 24, 2020

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Optimizing Platelet Inhibition in the Cath Lab at Tufts Medical Center

Carey Kimmelstiel, M.D., FACP, FACC, director, interventional cardiology, director, cardiac catheterization lab, Tufts ...

February 18, 2020

The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib).

News | Left Atrial Appendage (LAA) Occluders

Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial

February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess ...

February 03, 2020

Indications expanded for Ozempic and Rybelsus to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease

News | Pharmaceuticals

FDA Clears Semaglutide For Cardiac Risk Reduction in Diabetic Patients

January 29, 2020 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk's Ozempic ...

January 29, 2020

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals

Fruit Fly Hearts Show How to Keep Human Cardiac Muscle Young

January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies, a ...

January 09, 2020

$The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).$

News

Dapagliflozin Granted FDA Priority Review for Heart Failure With Reduced Ejection Fraction

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...

January 07, 2020

News | Pharmaceuticals

Study Finds Drug Therapy for High Triglycerides to Have a Sustained Effect Using Low Dosages

December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained and ...

December 30, 2019

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies

FDA Clears First Generics for Eliquis

December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of ...

December 27, 2019

Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.

Feature | Pharmaceuticals | Dave Fornell, Editor

FDA Expands Vascepa to Reduce Cardiovascular Events in Elevated Triglyceride Patients

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent ...

December 16, 2019

News | Antiplatelet and Anticoagulation Therapies

Low-dose Aspirin May Not Help African Americans Prevent Heart Disease

December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African ...

December 12, 2019

News | Cardiovascular Clinical Studies

Virtual Study to Track Statin-Related Adverse Events Being Undertaken by University of Connecticut and Hartford Healthcare

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

November 26, 2019

Heart failure VICTORIA TrIal a success. Dave Fornell

News | Heart Failure

Investigational Drug Vericiguat Reduced the Risk of Heart Failure Hospitalization in VICTORIA Trial

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of ...

November 21, 2019

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

Feature | AHA

ISCHEMIA Trial Results Find Interventions for Stable Heart Disease No better Than Drug Therapy

November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of ...

November 19, 2019

Feature | AHA | Dave Fornell, Editor

American Heart Association 2019 Late-breaking Trials

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at the ...

November 19, 2019